WO2004084993A1 - 心臓治療装置及び心臓治療方法 - Google Patents
心臓治療装置及び心臓治療方法 Download PDFInfo
- Publication number
- WO2004084993A1 WO2004084993A1 PCT/JP2004/003766 JP2004003766W WO2004084993A1 WO 2004084993 A1 WO2004084993 A1 WO 2004084993A1 JP 2004003766 W JP2004003766 W JP 2004003766W WO 2004084993 A1 WO2004084993 A1 WO 2004084993A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heart rate
- heart
- sensor
- nerve
- ventricular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36114—Cardiac control, e.g. by vagal stimulation
Definitions
- the present invention relates to a cardiac treatment apparatus and a cardiac treatment method for preventing the occurrence of lethal arrhythmias by electrical stimulation of the vagus nerve, and more particularly to controlling the allowable range of heart rate parameters in response to exercise stress. Is what you do. Background art
- FIGS. 20A and 20B show a heart structural diagram and an electrocardiogram waveform.
- the heart is made up of two atria and two ventricles.
- the atrium is the room that stores the returned blood
- the ventricle is the room that sends out the blood.
- Blood enters the right atrium from the vena cava and is sent from the right atrium to the pulmonary artery via the right ventricle.
- Arterial blood which has taken oxygen from the lungs, enters the left atrium via the pulmonary veins and is sent from the left atrium to the aorta via the left ventricle.
- the ventricles have thicker muscles than the atria.
- a valve is provided.
- Heart failure is a condition in which the ventricles work poorly to pump blood, and most are left heart failure, in which the left ventricle is in poor condition.
- the heart beat counts about 100,000 times a day, depending on the individual. Then, a weak current is generated each time the heart beats. By detecting this current, the state of the heart can be known.
- the electrocardiogram shown in FIG. 2B shows the temporal change of the state of the heart.
- This electrocardiogram which is obtained during a normal medical examination with electrodes attached to the body surface, basically consists of multiple waves with amplitudes of a few milliports. As shown, the first wave coming is the P wave, This represents the current when the atrium (right and left atrium) is depolarized. The next big wave, called the QRS wave, appears when the ventricle contracts and pumps blood throughout the body.
- T wave is the current when the contracted ventricular muscles recover electrically, and this series of wave transitions is an electronic view of the process from contraction to relaxation of the heart muscles. It is.
- the time from the start of the P-wave, which indicates cardiac depolarization, to the start of the QRS wave, which indicates ventricular depolarization, is called the PQ interval.
- the start of the QRS wave, which indicates ventricular polarization, and the end of the T-wave, which indicates ventricular repolarization The time up to is called QT interval or QT time.
- sudden cardiac deaths especially those caused by heart disease, are called sudden cardiac deaths, the number of which is about 50,000 annually in the country.
- the immediate cause of sudden cardiac death is the development of hemodynamically disrupted ventricular tachycardia—ventricular fibrillation, called lethal arrhythmias.
- the ventricle In ventricular tachycardia, the ventricle pulsates abnormally prematurely, and in ventricular fibrillation, the individual muscle fibers constituting the ventricle begin to excite in a chaotic manner, and the entire ventricle trembles little by little.
- a fatal arrhythmia occurs, the pump function of the heart is reduced or lost, and it becomes impossible to pump the necessary blood to the whole body, causing loss of consciousness due to a decrease in cerebral blood flow. Failure to take action can result in death.
- Implantable cardioverter defibrillators are being used to treat patients at risk of sudden cardiac death.
- the ICD performs defibrillation by detecting the occurrence of ventricular tachycardia / ventricular fibrillation by giving an electric shock to the heart.
- the ICD operates after a heart abnormality has occurred, so to speak, is a treatment device for coping therapy.
- a large electric shock for defibrillation is used in the heart. There is a risk of damaging the tissue.
- the autonomic nervous system has a sympathetic nervous system and a parasympathetic nervous system, and the parasympathetic nervous system of the heart is the vagus nerve.
- Increased (strained) sympathetic activity increases heart activity (heart rate and cardiac output), and increased vagal activity decreases heart activity (heart rate).
- Activities in the sympathetic and vagus nerves are usually antagonistic, and the heart is stably controlled to maintain an appropriate resting heart rate, approximately 70 kPa / min. That is, when the sympathetic nerve is nervous, it acts on the heart excitably, whereas when the vagus nerve is nervous, it acts on the heart in a depressing manner.
- Vagal tone reduces heart rate, but lower heart rate reduces the incidence of ventricular premature contractions that induce fatal arrhythmias, and reduces myocardial oxygen consumption as heart rate decreases. Prevents or ameliorates myocardial hypoxia and prevents myocardial ischemia-myocardial infarction and associated fatal arrhythmias.
- This device for treating cardiac arrhythmias is intended to prevent or stop cardiac arrhythmias and maintain proper functioning of the heart through stimulation of heart tissue and stimulation of the vagus nerve.
- This cardiac therapy device not only compares the pre-set tachycardia detection interval threshold with the patient's pulsation, but also changes the ST portion (voltage) of the electrocardiogram suggesting acute myocardial ischemia.
- We also examined other factors related to ventricular tachycardia By stimulating the vagus nerve on the basis of this, it is possible to suppress tachycardia.
- the cardiac arrhythmia treatment device includes a means for continuously measuring an electrocardiogram of a patient's heart, a means for detecting a characteristic of the electrocardiogram indicating tachycardia, a means for initializing a memory of a series of characteristics, and one or more Means for delivering electrical stimulation to the patient's nervous system, and means for initializing a series of characteristics of the electrocardiogram following delivery of the stimulation.
- Excessive stimulation of the vagus nerve may cause discomfort due to suppression of physiological heart activity, discomfort, shortness of breath due to a small increase in heart rate, shortness of breath, palpitations, fatigue, effects on organs other than the heart For example, indigestion or nausea due to excessive secretion of stomach acid, insulin, glucagon, etc.
- induction of vagus nerve There is a problem of induction of vagus nerve, and conversely, if the stimulation to the vagus nerve is weak, sufficient effect cannot be obtained, and the tolerance to stabilize the heart rate and control the vagus nerve stimulation according to the situation It was desired to do so.
- the device described in Patent Document 1 incorporates a simple clock using a clock signal supplied to operate an electronic circuit of the device, and based on this clock, a preset time, for example, When the bedtime or activity time is reached, the allowable range of heart rate stabilization by vagus nerve stimulation is changed to the range previously associated with bedtime or activity time, thereby increasing the allowable range of heart rate stabilization.
- Attempt to achieve daily fluctuation Things However, life patterns are always fluctuating even in ordinary daily life, and especially when traveling abroad such that day and night are reversed, it cannot be handled at all.
- Patent Document 2 detects si (voltage) from electrocardiogram information, triggers nerve stimulation depending on whether or not the value exceeds a threshold value, and sets tachycardia / fibrillation in advance. Stimulating the vagus nerve to overcome the decrease in heart rate associated with stimulating the vagus nerve, and stimulating the heart so that the patient's heart rate is within an acceptable range
- the allowable range of the heart rate could not be controlled according to the situation.
- the ST value indicates the ischemic state of the myocardium and the degree of myocardial injury. Further, the ST value changes during the acute phase of ischemia, but returns to the normal level during the chronic phase.
- Controlling neural stimulation based on ST values has made it difficult to achieve prophylaxis in a variety of everyday situations.
- sympathetic tone is increased by exercise and mental stress.
- the combination of organic lesions of the heart and increased sympathetic tone increases the possibility of fatal arrhythmias.
- the present invention indirectly detects the degree of sympathetic tone by detecting movement, mental stress, and the like with a sensor. If it is determined from the detected motor or mental stress that the sympathetic nerve excitation is intense, the heart rate should be stabilized within a narrower range to prevent the occurrence of lethal arrhythmias.
- a heart treatment apparatus of the present invention includes a nerve stimulating unit that generates a nerve stimulating signal for stimulating a vagus nerve, and a stimulating vagus nerve by the nerve stimulating unit.
- Heart rate threshold control means for setting a heart rate threshold value at the time of measurement, heart rate measurement means for measuring heart activity, heart rate comparison means for comparing the output of the heart rate measurement means with a heart rate threshold, and a sensor for sensing biological information Means, and the heart rate threshold control means controls the heart rate threshold in response to the output of the sensor means.
- the measurement of the heart activity is the measurement of the heart rate
- the nerve stimulating means generates a neural stimulation signal when the heart rate exceeds the heart rate threshold
- the cardiac therapy apparatus is characterized in that the measurement of the activity of the heart is the measurement of the heartbeat interval, and the nerve stimulation means generates a nerve stimulation signal when the heartbeat interval falls below the heartbeat threshold.
- the cardiac treatment apparatus of the present invention includes nerve stimulation signal control means for controlling a parameter of the nerve stimulation signal in response to an output of the sensor means, wherein the parameters of the nerve stimulation signal include an inter-pulse period, Pa At least one of the following: pulse width, number of pulses, pulse voltage, pulse current, delay time, rest time, number of repetitions, or a combination of at least one of these. I have.
- the sensor means detects ventricular contractility, and the ventricular contractility includes QT time, electrocardiogram area, pre-ejection time, stroke volume It is characterized by either ventricular pressure.
- the heart treatment apparatus is characterized in that the sensor means senses body movement, senses respiration, or senses blood.
- the heart treatment device of the present invention comprises: a nerve stimulation means for generating a nerve stimulation signal for stimulating a vagus nerve; and a heartbeat threshold control means for setting a heartbeat threshold when the vagus nerve is stimulated by the nerve stimulation means.
- Heart rate measuring means for measuring atrial activity; means for comparing the output of the heart rate measuring means with the heart rate threshold; sensor means for sensing ventricular contractility; and timing in response to atrial activity.
- the heart treatment apparatus of the present invention is characterized in that the sensor means for sensing the contractility of the ventricle is an electrocardiogram sensor, and the electrocardiogram sensor is either a QT time sensor or an electrocardiogram area sensor. ing.
- the apparatus further includes nerve stimulation signal control means for controlling parameters of the nerve stimulation signal in response to the output of the sensor means, wherein the parameters of the nerve stimulation signal include a period between pulses, a pulse width, a pulse number, and a pulse. It is characterized by being at least one of a source voltage, a pulse current, a delay time, a pause time, and a number of repetitions, or a combination of a plurality of these.
- the heart treatment method of the present invention comprises the steps of: sensing biological information; measuring a heart activity; measuring a heart rate; comparing a heart rate measurement result with a heart rate threshold; Stimulating the vagus nerve when it is determined that the activity is faster than the heart rate threshold, and changing the heart rate threshold in response to the biological information output. I have.
- the heart activity measurement is a heart rate measurement
- a neural stimulation signal is generated when the heart rate exceeds a heart rate threshold, or the heart activity measurement is a heart rate interval.
- This is a measurement and is characterized in that the nerve stimulation signal is generated when the heartbeat interval is less than a heartbeat threshold.
- the biological information is ventricular contractility
- the ventricular contractility is any of QT time, electrocardiogram area, pre-ejection time, stroke volume, and ventricular pressure. It is characterized by
- the cardiac treatment method of the present invention is characterized in that the biological information is a force relating to the patient's body movement, a force relating to the patient's respiration, or a force relating to the patient's blood.
- the parameters of the nerve stimulation signal are controlled in response to the biological information, and the parameters of the nerve stimulation signal include a period between pulses, a pulse width, a pulse number, a pulse voltage, a pulse current, It is characterized by being at least one of delay time, pause time, and number of repetitions, or a combination of a plurality of these.
- the heart treatment method of the present invention includes a step of measuring a heartbeat by measuring atrial activity, and a heartbeat ratio for comparing the heartbeat measurement result with a heartbeat threshold. Comparing the atrial activity with the heart rate comparing step, and stimulating the vagus nerve if the heart rate comparing step determines that the atrial activity is faster than the heart rate threshold; and sensing the ventricular contractility.
- Initiating the timing of the atrioventricular delay time in response to is compared with whether the measured atrioventricular delay time exceeds a predetermined set value, and stimulating the ventricle when the measured atrioventricular delay time exceeds the predetermined set value
- the step of sensing the contractility of the ventricle is performed by an electrocardiogram sensor, and the electrocardiogram sensor is either a QT time sensor or an electrocardiogram area sensor.
- the cardiac treatment method of the present invention controls the parameters of the nerve stimulation signal in response to the output of the sensor, and the parameters of the nerve stimulation signal include an inter-pulse period, a pulse width, and a pulse width. It is characterized in that at least one of the number of pulses, pulse voltage, pulse current, delay time, pause time, number of repetitions, or a combination of these is used. .
- the heart rate threshold at the time of stimulating a vagus nerve can be adjusted according to the excitement degree of a sympathetic nerve of a patient, the occurrence of a fatal arrhythmia can be adjusted.
- Prevention, as well as preservation of the patient's own cardiac activity, which is more physiological, increases the patient's exercise capacity, and avoids the side effects of neural stimulation and excessive reduction in heart rate be able to.
- the sympathetic nervous activity is high, the upper limit of the spontaneous heart rate for performing vagus nerve stimulation is set low to stabilize the heart rate within a narrow range, and the sympathetic nervous system excitement is reduced.
- FIG. 1 is a diagram showing a configuration example of a heart treatment apparatus according to a first embodiment of the present invention.
- FIG. 2 is a diagram showing the arrangement of electrode leads and stimulating electrodes used in the heart treatment apparatus of the present invention on the heart.
- FIG. 3 is a diagram illustrating a configuration example of a heart treatment apparatus according to a second embodiment of the present invention.
- FIG. 4 is a diagram illustrating a configuration example of a heart treatment apparatus according to a third embodiment of the present invention.
- FIG. 5 is a flowchart showing the operation of the heart treatment apparatus according to the first to third embodiments of the present invention shown in FIGS. 1, 3 and 4.
- FIG. 6 is a diagram illustrating a configuration example of a heart treatment apparatus according to a fourth embodiment of the present invention.
- FIG. 7 is a diagram showing a configuration example of the heart treatment apparatus according to the fifth and sixth embodiments of the present invention.
- FIG. 8 is a block diagram of a pre-ejection time sensor used as sensor means according to the fifth embodiment of the present invention.
- FIG. 9 is a block diagram of a stroke volume sensor used as sensor means according to the sixth embodiment of the present invention.
- FIG. 10 is a flowchart showing the operation of the heart treatment apparatus according to the fourth to sixth embodiments of the present invention shown in FIGS. 6, 7 and 8 and 9.
- FIG. 11 is a diagram showing a configuration example of the heart treatment apparatus according to the seventh and eighth embodiments of the present invention.
- FIG. 12 is a block diagram of a QT time sensor used as the sensor means of the seventh embodiment of the present invention.
- FIG. 13 is a block diagram of an electrocardiogram area sensor used as sensor means according to the eighth embodiment of the present invention.
- FIG. 14A is a waveform diagram showing an intraventricular electrocardiogram and QT time
- FIG. 14B is a waveform diagram showing an integration of the intraventricular electrocardiogram.
- FIG. 15 is a diagram showing the QT interval and the heart rate threshold.
- FIG. 16 is a flowchart showing the operation of the heart treatment apparatus according to the seventh embodiment of the present invention shown in FIGS. 11 and 12.
- FIG. 17 is a flowchart showing the operation of the cardiac treatment apparatus according to the eighth embodiment of the present invention shown in FIGS. 11 and 13.
- FIG. 18 is a diagram illustrating a configuration example of a heart treatment apparatus according to a ninth embodiment of the present invention.
- FIG. 19 is a flowchart showing the operation of the cardiac treatment apparatus of the ninth embodiment of the present invention shown in FIG.
- FIG. 2OA is a diagram showing the structure of the heart
- FIG. 20B is an example of an electrocardiogram measured by placing an electrode on the body surface.
- the heart treatment apparatus 1 of the present invention includes a ventricle stimulating unit 2 for generating a ventricular stimulation pulse for stimulating a right ventricle 28 of a heart 27, a ventricular contraction detecting unit 3 for detecting a contraction of the right ventricle 28, and a heart 27.
- Atrium that stimulates the right atrium 2 9
- Atrial stimulator 4 that generates stimulation pulses
- atrial contraction detector 5 that detects contraction of right atrium 29
- nerve stimulator 6 that generates nerve stimulation signals that stimulate the vagus nerve 32
- neural stimulation signal generation Control unit 7 that controls timing
- heart rate monitor unit 8 that detects heart rate from atrial contraction and gives control signal to control unit 7
- atrial stimulation interval timer 9 that counts the time interval of atrial stimulation
- AVD atrioventricular delay
- the AVD comparison unit 15 that outputs an output when it exceeds, the body movement sensor 16 that detects body movement, the body movement detection timer 17 that measures the timing of body movement detection, and the tie that is measured by the body movement detection timer 17 from the body movement detecting unit 1 8 which takes in the output from Karadadose capacitors 1 6 Mi ring configured t - in general, is the body motion sensor 16, a piezoelectric sensor or an acceleration sensor is used.
- the sensor is installed inside the housing of the cardiac therapy device 1 that is implanted under the chest and mounted directly on the housing or on a circuit board.
- a piezoelectric sensor stress is applied to a piezoelectric crystal by physical movement, and the crystal generates an electrical signal.
- the acceleration sensor generally has a structure having a cantilever, and the acceleration causes the beam to move and displace, thereby generating an electric signal.
- the body movement of the patient can be detected from the frequency, intensity, or intensity within a certain frequency of the electrical signal.
- the control unit 7 responds to the body movement detected by the body movement detection unit 18 ⁇
- It comprises a heart rate threshold control section 19 for changing the threshold of the heart rate, and a nerve stimulation signal control section 20 for receiving a signal from the heart rate monitor section 8 and controlling the nerve stimulation section 6.
- the heart rate monitoring unit 8 measures the heart rate with the output of the atrial contraction detecting unit 5 and resets the counting, and resets the counting with the output of the comparing unit 11, that is, the signal that triggers the atrial stimulating unit 4.
- the ventricular stimulating unit 2 and the ventricular contraction detecting unit 3 are connected to the ventricular stimulating / detecting electrode 24 by a common ventricular electrode lead 23, and the atrial stimulating unit 4 and the atrial contraction detecting unit 5 are similarly connected to the atrial electrode. It is connected to atrial stimulation / detection electrode 26 via lead 25.
- the ventricular stimulation Z detection electrode 24 and the atrial stimulation / detection electrode 26 are arranged in the right ventricle 28 and right atrium 29 of the heart 27.
- Electrodes for the heart there are a myocardial electrode implanted in the heart muscle, so-called myocardium, and a catheter electrode for inserting the electrode through the vena cava to the heart.
- Figure 2 shows an example of a catheter electrode, but both the ventricular electrode lead 23 and the atrial electrode lead 25 are initially guided from the vena cava to the right atrium ⁇ 9 of the heart 27.
- the atrial electrode lead 25 inserted into the right atrium 29 from the vena cava, hooks the J-shaped bent tip into the bag-shaped right atrial appendage protruding from the right atrial wall. It is inserted, and the atrial stimulation detection electrode 26 is placed so as to contact the inner wall of the right atrial appendage.
- the ventricular electrode lead 23 which is introduced into the right atrium 29 from the vena cava, enters the right ventricle 28 through the atrioventricular valve, and is provided at the distal end of the ventricular electrode lead 23.
- Ventricular stimulation Z detection electrode 24 is placed so as to contact the lowermost part of right ventricle 28.
- the nerve stimulating unit 6 supplies the nerve stimulating Connected to the pole 31, the nerve stimulation electrode 31 is fixed while being wound around the vagus nerve 32.
- the region around which the nerve stimulation electrode 31 is wound is preferably the neck region or the right center position of the lateral carotid artery.
- the nerve stimulation electrode 31 can also be arranged so as to stimulate the vagus nerve 32 adjacent to the blood vessel wall by placing a catheter electrode in the blood vessel. In that case, the placement region is preferably in the subclavian vein.
- the atrial contraction detecting section 5 detects contraction of the right atrium 29
- the atrial contraction detecting section 5 outputs the output to the heart rate measuring section 21 of the heart rate monitoring section 8 and the OR circuit 1 Send to 2.
- the heart rate measuring unit 21 measures the heart rate from the counting content including the time information at the time of detecting the atrial contraction, and sends the measurement result to the heart rate comparing unit 22.
- the heart rate measuring unit 21 resets the counting content and starts counting the time interval until the detection of the next atrial contraction.
- the heart rate comparison unit 22 receives the measurement value of the heart rate measurement unit 21, that is, the value corresponding to the heart rate per minute calculated from the time interval until atrial contraction detection, to the heart rate threshold control unit 19 of the control unit 7. When the threshold value is exceeded, the activity of the heart is accelerated, so that an output is generated and supplied to the nerve stimulation signal control unit 20 of the control unit 7.
- the nerve stimulation signal control section 20 receives this signal, controls the nerve stimulation section 6 and stimulates the vagus nerve 32.
- the output of the atrial contraction detection unit 5 is also supplied to the atrial stimulation interval timer 9 via the OR circuit 12, and resets the atrial stimulation interval timer 9.
- the atrial stimulation interval timer 9 is reset based on the output supplied through the OR circuit 12 every time a spontaneous atrial event or an event due to atrial stimulation occurs, and counts the time interval of the atrial event occurrence. Do. Then, the measured value is stored in the atrial stimulation interval setting value storage unit 10. When the value matches the fixed value, an output is generated from the comparison unit 11 and the output is supplied to the atrial stimulating unit 4 to perform atrial stimulation. At the same time, the output of the comparison unit 11 is supplied to the atrial stimulation interval timer 9 via the OR circuit 12 and reset, as in the detection of atrial contraction.
- the atrial spontaneous event is detected by the atrial contraction detection unit 5.
- the atrial stimulation interval timer 9 is reset each time, and its count value does not reach the set value stored in the atrial stimulation interval set value storage unit 10. No output is produced and no atrial stimulation occurs.
- the output of the comparison unit 11 is supplied to the AVD timer 13 via the OR circuit 12 together with the output of the atrial contraction detection unit 5, and the counting of the AVD timer 13 is started. Further, the signal for triggering the atrial stimulating unit 4 which is the output of the comparing unit 11 is sent to the heart rate measuring unit 21 of the heart rate monitoring unit 8 so that the heart rate measuring unit 21 is reset. I have. At this time, unlike the case of detecting atrial contraction, the heart rate measuring unit 21 only resets the counting content, but does not measure the heart rate and output the subsequent measurement result. Thus, only when spontaneous atrial contraction occurs, the heart rate measuring unit 21 calculates a heart rate equivalent value from the preceding atrial event and the detected time interval of atrial contraction, and this heart rate value is controlled. When the threshold exceeds the threshold value stored in the heart rate threshold control section 19 of the section 7, the heart rate comparison section 22 generates an output and supplies the output to the nerve stimulation signal control section 20 of the control section 7. .
- the AVD timer 13 measures the time from contraction or stimulation of the atrium to contraction of the ventricle.
- the AVD timer 13 starts time measurement by contraction of the atrium or stimulation of the atria, and the ventricular contraction detection unit 3 When the ventricle contraction is detected, the timing is stopped.
- the ventricle contraction detection unit 3 does not detect the contraction of the right ventricle 28 within the predetermined set value stored in the AVD set value storage unit 14, the count value of the AVD timer 13 is used as the AVD set value storage unit.
- an output is emitted from the AVD comparing section 15 and sent to the ventricular stimulating section 2.
- the ventricular stimulating unit 2 receives this signal and performs ventricular stimulation via the ventricular electrode lead 23 and the ventricular stimulating electrode 24.
- the nerve stimulation signal control unit 20 of the control unit 7 Upon receiving the signal from the heartbeat comparing unit 22, the nerve stimulation signal control unit 20 of the control unit 7 sends an output to the nerve stimulation unit 6, and the nerve stimulation unit 6 has a nerve electrode lid 30 and a nerve stimulation electrode. 'Try to stimulate the vagus nerve 3 2 through 3 1.
- the body motion sensor 16 can measure the degree of excitement of the sympathetic nerve by detecting the acceleration or vibration of the body. This is because intense exercise increases body movement changes (acceleration and vibration), and at the same time, excites the sympathetic nerves.
- the output from the body movement sensor 16 is detected by the body movement detection unit 18 at appropriate time intervals measured by the body movement detection timer 17, and the body movement during each measurement is measured. You.
- the threshold of the heart rate threshold controller 19 can be changed by the detected body motion, so that the heart rate limit at which nerve stimulation should be performed can be changed according to the patient's situation.
- FIG. 3 is a block diagram showing a second embodiment of the heart treatment apparatus of the present invention.
- the difference from the first embodiment shown in FIG. 1 is that a respiration sensor is used in place of the body motion sensor 16.
- the same parts as those in the block diagram of FIG. 1 are denoted by the same reference numerals, and description thereof is omitted.
- the respiration sensor includes an impedance measurement section 34 connected to the atrial electrode lead 25, a respiration detection section 35 to which the output of the impedance measurement section 34 is added, and a respiration detection timing. And a respiration detection timer 33 that measures
- the impedance measuring unit 34 is a heart treatment device that is implanted under the chest through the atrial electrode lead 25.
- Impedance is obtained by superimposing and applying a constant current measurement waveform of a strength that does not stimulate the right atrium 29 between the titanium housing 1 and the atrial stimulation / "detection electrode 26" and measuring the voltage at both ends.
- the respiratory sensor can detect the expansion or contraction state of the rib cage from the impedance change between the right atrium 29 and the chest, and thus can know the respiratory state of the patient.
- the respiratory sensor may be configured so that the impedance measuring unit 34 and the ventricular electrode lead 23 are connected to know the respiratory condition of the patient from a change in impedance between the right ventricle 28 and the chest. it can. . ' .
- the operation of the heart treatment apparatus When the sympathetic nerve excitement increases due to exercise or stress, expiration (respiratory rate and respiratory volume) intensifies, and this is measured via the atrial electrode lead 25 and the impedance measurement unit 3 of the respiratory sensor. In Fig. 4, it can be regarded as a change in impedance.
- the respiration detection unit 35 processes the impedance change measured by the impedance measurement unit 34 at an appropriate time counted by the respiration detection timer 33, and the respiration rate is determined based on the speed of the impedance change.
- the respiratory volume is detected from the magnitude of the impedance change, and the heart rate threshold value of the heart rate threshold controller 19 is changed according to the respiratory rate and the respiratory volume. Then, the selected heart rate threshold value is supplied to the heart rate comparison unit 22 and compared with the heart rate measured by the heart rate measurement unit 21.
- FIG. 4 is a block diagram showing a third embodiment of the heart treatment apparatus of the present invention.
- the difference from the first embodiment and the second embodiment of the present invention shown in FIGS. 1 and 3 is that the excitement of the sympathetic nerve is also detected.
- This is the configuration of the sensor part.
- a ventricular stimulation / detection electrode 24 disposed in the right ventricle 28 or a blood sensor electrode 36 formed integrally with the ventricle electrode lead 23 is used.
- the same parts as those in the block diagrams of FIGS. 1 and 3 are denoted by the same reference numerals.
- the blood sensor 36 is arranged in the ventricle, but may be integrated with the atrial electrode instead of the ventricular electrode.
- the biological information detected by the blood sensor 36 includes central venous blood temperature, venous oxygen saturation, blood pH, and catecholamine content in blood, all of which are autonomous due to exercise or stress. It is related to the excitement of nerves (especially sympathetic nerves).
- the blood sensor 36 is drawn as a separate body from the ventricular stimulation Z-detection electrode 24 or the ventricular electrode lead 23 for the sake of simplicity. Inside 7 is integrally formed.
- the information from the blood sensor 36 arranged in the right ventricle 28 is sent to the blood information detection unit 37, and is detected at the timing measured by the blood information detection timer 38. Then, the output of the blood information detection unit 37 is supplied to the heart rate threshold control unit 19 of the control unit 7. Hereinafter, the same operation as that of the second embodiment shown in FIG. 3 is performed.
- the atrial stimulation interpal timer 9 is started (step S1).
- an initial value of the heart rate of the heart rate threshold controller 19 is set (step S2), and a biological information detection timer used for various sensors is started (step S3), and the system is initialized.
- the biological information is body movement in the first embodiment, In the third embodiment, it is respiration, and in the third embodiment, it is blood.
- the atrial contraction detecting section 5 determines whether or not atrial contraction has been detected (step S4). If an atrial contraction is detected in the judgment step S4, the heart rate measurement unit 21 starts measuring the heart rate (step S5), and resets the atrial stimulation interpulse timer 9 power S reset. (Step S6).
- step S7 it is determined whether or not the heart rate measured by the heart rate measurement unit 21 has reached the heart rate threshold set by the heart rate threshold control unit 19 (step S7). If it is determined that the heart rate measurement value exceeds the threshold set in the heart rate threshold control section 19, an output is obtained from the heart rate comparison section 22 and passes through the nerve stimulation signal control section 20 to the nerve stimulation section 6. This stimulates the vagus nerve 32 (step S8).
- the vagus nerve 32 is not stimulated, and the atrial contraction is detected.
- the output of the unit 5 is applied to the AVD timer 13 via the OR circuit 12, and the AVD timer 13 starts measuring time (step S9).
- step S10 when the contraction of the atrium is not detected in the determination step S4, it is determined whether or not the biological information detection timer has timed out (step S10). If it is determined that the biological information detection timer has timed out, the heart rate threshold of the heart rate threshold control unit 19 is adjusted to a predetermined value based on the detected biological information (step S11). The biological information detection timer is reset (step S12). If it is determined in determination step S10 that the biological information detection timer has not timed out, the heart rate threshold of the heart rate threshold control unit 19 is not adjusted, and the biological information detection timer is not reset. Proceed to the next step S13.
- the atrial stimulation interval timer 9 it is determined whether or not the atrial stimulation interval timer 9 has timed out, that is, the time measured by the atrial stimulation interval timer 9 exceeds the set value of the atrial stimulation interval set value storage unit 10. Is determined. If the measured time of the atrial stimulation interval timer 9 exceeds the set value of the atrial stimulation interval set value storage unit 10, the comparison unit 11 outputs an output, and the atrial stimulation unit 4 outputs the right atrium 29. Is stimulated (step S 14). At the same time, the output of the comparison unit 11 resets the count content of the heart rate measurement unit 21 and resets the atrial stimulation interval timer 9 via the OR circuit 12 (step S15). . At the same time, the AVD timer 13 is also reset, and the AVD timer 13 starts measuring time (step S9).
- the process returns to the determination step S4. Wait for the detection of tuft contraction.
- the ventricular contraction detecting section 3 determines whether ventricular contraction has been detected (step S16). If a ventricular contraction is detected, the count of the AVD timer 13 is stopped (step S17), and the process returns to the decision step S4 to wait for the detection of the next atrial contraction. If no ventricular contraction is detected in the determination step S16, it is determined whether the biological information detection timer has timed out (step S18), and the biological information detection timer has expired. When the determination is made, the heart rate threshold of the heart rate threshold controller 19 is adjusted to a predetermined value based on the detected biological information (step S19), and the biological information detection timer is reset (step S19). 2 0).
- the heart rate threshold of the heart rate threshold controller 19 is not adjusted, and the biological information detection is not performed.
- the timer is not reset, and the process proceeds to the next step S21.
- determination step S21 it is determined whether or not the AVD timer 13 has timed out. That is, it is determined whether the count value of the AVD timer 13 has exceeded the reference atrioventricular delay time set in the AVD set value storage unit 14 and, if so, output from the AVD comparison unit 15. Is emitted, and the right ventricle 28 is stimulated by the ventricle stimulating unit 2 (step S22). If it is determined in determination step S21 that the AVD timer 13 has not timed out, the flow returns to determination step S16 to wait for detection of ventricular contraction.
- the state of body movement, respiration, and blood are detected, and the upper limit for stimulating the vagus nerve is detected based on the biological information.
- the heart rate By adjusting the heart rate, it is possible to stimulate the vagus nerve in a state that is optimal for the patient and with a small burden.
- FIG. 1 A block diagram of FIG.
- the same components as those in the first to third embodiments of the present invention are denoted by the same reference numerals.
- the fourth embodiment of the present invention shown in FIG. 6 differs from the first to third embodiments in that a ventricular contractile ventricular pressure sensor 40 is used as a biological information detection sensor.
- a differentiating circuit (dp / dt) for detecting the time change rate (time derivative) dp / dt of the intraventricular pressure detected by the pressure sensor 41 disposed in the ventricle is used.
- / dt) 4 2 and a maximum value holding circuit (max dp / dt) 4 3 that holds the maximum value of the output of this differentiating circuit.
- the output of the ventricular contraction detecting unit 3 and the output of the AVD comparing unit 15, that is, a signal that triggers the ventricular stimulating unit 2 are supplied, and the output is supplied to the maximum value holding circuit (max dp / dt) 43.
- An OR circuit 39 is newly added to supply the t maximum value holding circuit (max dp / dt) 43. The output from this OR circuit 39 is Start monitoring the output of the differentiating circuit 42 at the timing of, and hold the maximum value.
- the pressure sensor 41 measures the pressure when the ventricle contracts, and is usually provided in the ventricular stimulation Z detection electrode 24 or the ventricular electrode lead 23. Then, the pressure in the ventricle is measured by the pressure sensor 41 and sent to the differentiating circuit 42.
- the differentiating circuit 42 differentiates the signal from the pressure sensor 41, obtains dp / dt, and supplies it to the maximum value holding circuit 43.
- the maximum value holding circuit 43 sets the timing of the output of the OR circuit 39, i.e., within a predetermined period, for example, 100 ms ec from detection of ventricular contraction or timing of stimulation to the ventricle.
- the maximum value of the output of the differentiation circuit 42 is held, and the maximum differentiation value max dp / dt is obtained.
- the held max dp / dt is sent to the heart rate threshold controller 19 of the controller 7, and the heart rate according to the value of the max dp / dt is determined as a threshold for performing nerve stimulation.
- the magnitude of the exercise mental stress can be detected from the value of max dp / dt.
- the upper limit heart rate for performing nerve stimulation is made different between when max dp / dt is large and when max dp / dt is small.
- FIG. 7 is a block diagram showing the fifth and sixth embodiments of the heart treatment apparatus of the present invention.
- the difference from the fourth embodiment shown in FIG. 6 is that a ventricular contractile impedance sensor 50 is used as a sensor for detecting biological information. Since the other block configurations are the same as those of the fourth embodiment, the same block configurations are denoted by the same reference numerals.
- FIGS. 8 and 9 show specific examples of the ventricular contractile impedance sensor 50.
- FIG. FIG. 8 shows the use of the pre-ejection time sensor 51 as the ventricular contractile impedance sensor 50.
- an embodiment using the stroke volume sensor 55 shown in FIG. 9 as the ventricular contractile impedance sensor 50 will be described below as a sixth embodiment of the present invention.
- the ventricular pre-ejection time is the time from the onset of ventricular depolarization (detection of ventricular contraction or ventricular stimulation) until the ventricle actually begins to eject blood. From this ventricular pre-ejection time, it is possible to sense the degree of exercise and mental stress.
- the pre-ejection time sensor 51 is provided with a pre-ejection time measurement section 52 for starting ventricle contraction detection or ventricular stimulation as a trigger and measuring time.
- An impedance measurement section 53 for monitoring a change in ventricular volume.
- a ventricular ejection detection unit 54 that receives the output of the impedance measurement unit 53 and determines that the ejection of blood has started when the ventricular volume has a predetermined decrease.
- the output of the ventricular contraction detecting section 3 and the output of the AVD comparing section 15 are supplied to an OR circuit 39. Therefore, an output is obtained from the OR circuit 39 when the ventricle contraction is detected or when the ventricle is stimulated, and this output is obtained by measuring the pre-ejection time of the time pre-ejection sensor 51 (FIG. 8). It is supplied to part 52 and the measurement of the pre-ejection time is started. Then, the ventricular stimulation / detection electrode 24 is connected to the impedance measuring section 53 in FIG. 8 via the ventricular electrode lead 23, and the impedance measuring section 53 has a fluctuating ventricular volume. As a change in impedance, the change in volume of the ventricle is detected.
- the output of the impedance measuring section 53 is sent to the ventricular ejection detecting section 54, and the ventricular ejection detecting section 54 monitors the output from the impedance measuring section 53, that is, changes in the impedance of the ventricle. In volume If there is a constant decrease, it is determined that the ejection of blood has started, and the timing of the pre-ejection time timer 52 is stopped. The ventricular ejection time measured in this way is sent to the heart rate threshold control unit 19 of the control unit 7 in Fig. 7 and the upper limit rate of the heart rate at which nerve stimulation is performed according to the ventricular pre-ejection time. Is controlled and selected.
- FIG. 9 is a block diagram showing a configuration of a stroke volume sensor 55 which is a second example of the ventricular contractile impedance sensor 50 shown in FIG.
- the stroke volume is the volume of the end-diastolic ventricular volume minus the end-systolic ventricular volume in one ventricular contraction, and the magnitude of the motor-mental stress is also calculated from the stroke volume. It is something you can know.
- the sixth embodiment of the present invention employs the stroke volume sensor 55 shown in FIG. 9 as the ventricular contractility impedance sensor 50 shown in FIG.
- the stroke volume sensor 55 shown in FIG. 9 includes an end-diastolic volume detector 56 that detects ventricular contraction or ventricular stimulation as a trigger, and detects an end-diastolic volume of the ventricle.
- the end-systole which detects the minimum value of ventricular volume as the end-systolic volume from the output of the impedance measuring unit 57 following detection of the end-diastolic volume, and the end-diastolic volume following detection of the end-diastolic volume
- the stroke volume calculation unit 5 that calculates the stroke volume of the ventricle by subtracting the output of the end-systolic volume detection unit 58 from the output of the volume detection unit 58 and the end-diastolic volume detection unit 56 Consists of nine.
- the OR circuit 39 performs the ventricular stimulation when the ventricle contraction is detected. In this case, an output is obtained, and this output is supplied to the end-diastolic volume detector 56 of the stroke volume sensor 55 (FIG. 9).
- the impulse connected to ventricular stimulation / contraction electrode 24 One dance measuring section 57 calculates the volume of the ventricle from the measured impedance, and sends it to the end diastolic volume detecting section 56 and the end systolic volume detecting section 58.
- the end-diastolic volume detecting unit 56 detects the ventricular volume at the time of detecting ventricular contraction or at the time of ventricular stimulation based on the output from the impedance measuring unit 57, and sets this volume as the ventricular end-diastolic volume.
- the end-systolic volume detecting unit 58 monitors the output of the impedance measuring unit 57 and detects the minimum value of the ventricular volume as the end-ventricular volume.
- the stroke volume calculation unit 59 calculates the output difference between the end-diastolic volume detector 56 and the end-systolic volume detector 58, that is, the difference between the end-diastolic ventricular volume and the end-systolic ventricular volume, The calculation result is sent as a stroke volume to the heart rate threshold control unit 19 of the control unit 7 in FIG. 7 (the heart rate threshold control unit 19 uses the stroke volume information to calculate the amount of exercise and The degree of sympathetic nerve excitement due to enthal stress is captured, and the upper limit of the heart rate at which nerve stimulation is performed is set accordingly.
- the atrial stimulation interpulse timer 9 is started (step S30), and an initial value of the heart rate threshold is set (step S31).
- the atrial contraction detecting section 5 determines whether or not atrial contraction has been detected (step S32).
- heart rate measurement is started (step S33), and then the atrial stimulation interpal timer 9 is reset to start counting (step S34).
- step S35 it is determined whether the heart rate measurement value has exceeded the heart rate threshold set in step 31 (step S35). If the heart rate measured by the heart rate measurement unit 21 exceeds the heart rate threshold value (initial value) set in the heart rate threshold control unit 19, an output is issued from the heart rate comparison unit 22 and the nerve stimulation signal control unit Stimulation of vagus nerve 3 2 through 20 and nerve stimulating unit 6 , Is performed (step S36).
- step S32 it is determined whether or not the atrial stimulation interval timer 9 has timed out, that is, the time measured by the atrial stimulation interval timer 9 is atrial. It is determined whether the set value stored in the stimulus interval set value storage section 10 has been exceeded (step S37). Then, when it is determined that the time-out has occurred, an output is issued from the comparing section 11 to the atrial stimulating section 4, and the atrial stimulation is performed (step S38). Also, the counting content of the heart rate measuring section 21 is reset, and at the same time, the atrial stimulation interval timer 9 is reset (via the OR circuit 12) (step S39).
- the process proceeds to the next step S40 without stimulating the vagus nerve 32, and the judgment step S40 is performed. If it is determined in 37 that the atrial stimulation interval timer 9 has not timed out, the flow returns to the decision step S32 and waits for the detection of atrial contraction.
- the A / D timer 13 starts counting (step S4). 0). Subsequently, it is determined whether or not the ventricle contraction is detected by the ventricle contraction detection unit 3 (step S41). If a ventricular contraction is detected in this judgment step S41, the counting of the AVD timer 13 is stopped (step S42), and if no ventricular contraction is detected in the judgment step S41. It is determined whether the AVD timer 13 has timed out, that is, whether the set value stored in the AVD set value storage unit 14 has been exceeded (step S43).
- step S44 an output is issued from the AVD comparison unit 15 to the ventricle stimulating unit 2, and ventricular stimulation is performed (step S44).
- the ventricular pressure (second time) is detected by the sensor means of each embodiment.
- pre-ejection time (fifth embodiment)
- stroke volume (sixth embodiment) are detected (step S45).
- biological information relating to exercise and mental stress detected by the sensor means of each embodiment is sent to the heart rate threshold control section 19 of the control section 7, and the optimum heart rate according to the patient is obtained. It is adjusted to a number threshold (step S46).
- FIG. 11 is a block diagram showing the seventh and eighth embodiments of the present invention.
- the seventh embodiment uses the QT time sensor 70 shown in FIG. 12 as the ventricular contractile electrocardiogram sensor 60, and the electrocardiogram area sensor 75 shown in FIG. A mode in which is adopted will be described below as an eighth embodiment.
- the configuration different from the first to sixth embodiments shown in FIGS. 1, 3 to 4 and 6 to 9 is that a ventricular contractile electrocardiogram sensor 60 is used,
- the point is that two types of setting values for D (atrioventricular delay time) are provided and used by switching. That is, in the seventh and eighth embodiments shown in FIG. 11, the ventricular contractile electrocardiogram sensor 60 for detecting the patient's living body information from the electrocardiogram information, the ventricular stimulating unit 2 and the ventricular contraction detecting unit 3
- the outputs of the connected ventricular contraction detection continuation counter 65, the ventricle contraction detection continuation count set value storage unit 64, and the ventricle contraction detection continuation counter 65 and the ventricle contraction detection continuation count set value storage unit 64 are supplied.
- the ventricle contraction detection continuation count comparison unit 66 the first AVD storage unit 61 that stores the first AVD set value that is the normal atrioventricular delay time, and the normal atrioventricular delay time
- a second AVD storage section 62 for storing a short second AVD set value, and an AVD selection section 6 for selecting one of the first AVD storage section 61 and the second AVD storage section 62 3 is added.
- the QT time sensor 70 used as one form of the ventricular contractile electrocardiogram sensor 60 is shown in FIG. 12, and its configuration is provided by the output of the AVD comparison unit 15 in FIG. 11.
- a QT timekeeping unit 7 1 It consists of a QT timekeeping unit 7 1 and a T-wave detector 7 2, which supplies an intraventricular ECG from the ventricular detection electrode 24 only when ventricular stimulation is performed and detects a T-wave from this intraventricular ECG. Is done.
- the output of the T-wave detector 72 is supplied to a QT timer 71, where the QT time is measured and supplied to the heartbeat threshold controller 19 of the controller 7 in FIG. Have been.
- the electrocardiogram area sensor 75 shown in FIG. 13 is also used as one of the ventricular contractile electrocardiogram sensors 60.
- the electrocardiogram area sensor 75 includes an integration circuit 76 supplied with the ventricular electrocardiogram signal from the ventricle detection electrode 24 and the output of the AVD comparison section 15, and a negative maximum value of the output of the integration circuit 76. It comprises a negative maximum value detecting section 77 for detecting.
- FIG. 1 This intraventricular electrocardiogram is slightly different from the normal electrocardiogram shown in Fig. 20B with electrodes attached to the body surface. That is, in the ventricular electrocardiogram, there is almost no P wave for observing atrial contraction, and it is composed of a QRS wave starting from ventricular stimulation and a T wave having a different polarity from the QRS wave.
- the T wave is the wave that comes out when the ventricular contraction relaxes, that is, when the ventricular excitement ends.
- the QT time is the time from when the right ventricle is stimulated to depolarize the right ventricular muscle until the right ventricular muscle repolarizes and returns.
- the QT time takes the time derivative of the T wave and measure the QT time with the point at which the derivative (slope) becomes the negative maximum as the T point.
- This QT time is typical biological information relating to the contractility of the ventricle, and is in a normal state, that is, about 400 ms in a normal state, but when there is intense exercise stress. If the sympathetic nervous activity is increased in some cases, it becomes shorter and may be less than half of normal.
- the waveform diagram shown in FIG. 14B is a waveform diagram obtained by integrating the intraventricular electrocardiogram shown in FIG. 14A by the integration circuit 76 of the electrocardiogram area sensor 75 (FIG. 13).
- the QRS wave negative polarity
- the negative area value increases monotonically, but the T wave is opposite to the QRS wave. Since the polarity is positive, the negative integration value changes in the decreasing direction when the T wave is integrated.
- the negative maximum value of the ECG area is the value of the linear portion from the point S at which the integration of the QRS wave ends to the point at which the detection of the T wave starts (tentatively “X”).
- the negative maximum value detecting section 77 detects the above value, and sends the negative integrated maximum value as biological information to the heartbeat threshold value control section 19 of the control section 7 in FIG. 11.
- the atrial contraction detecting section 5 detects the contraction of the right atrium 29, the atrial contraction detecting section 5 sends the output to the AVD timer 13 via the OR circuit 12 and the AVD The timer 13 starts counting.
- the AVD selection unit 63 selects the normal AVD (atrioventricular delay time) setting value stored in the first AVD storage unit 61, for example, 150 ms.
- AVD atrioventricular delay time
- spontaneous ventricular contraction occurs after the start of the AVD timer 13 and before the set value stored in the first AVD storage unit 61 is counted.
- the D timer 13 is stopped by the output of the ventricular contraction detecting section 3 each time. For this reason, the AVD timer 13 Do not count up to the set value stored in the first AVD storage unit 61 selected in. Therefore, in this case, the output from the AVD comparing section 15 is not obtained, and the ventricular stimulating section 2 is not supplied with the output of the AVD comparing section 15, so that forced ventricular stimulation is not performed.
- the output from the ventricular contraction detection unit 3 cannot be obtained. 13 continues counting without stopping. That is, the AVD timer 13 continues counting until the value matches the set value stored in the first AVD storage unit 61 selected by the AVD selection unit 63. An output is generated from the comparator 15.
- the output of the AVD comparison unit 15 is sent to the ventricle stimulating unit 2, passes through the ventricular electrode lead 23, and stimulates the right ventricle 28 by the ventricular stimulation electrode 24. At the same time, the output of the AVD comparison section 15 is applied to the ventricle contraction detection continuation counter 65, and the ventricle contraction detection continuation counter 65 is reset. The output of the AVD comparing section 15 is supplied to the QT time measuring section 71 of the QT time sensor 70 shown in FIG. 12 to start the QT time measuring section 71.
- the ventricle contraction detection continuation counter 65 reset by the output of the AVD comparison unit 15, that is, the signal that triggers the ventricle stimulation unit 2.
- the ventricle contraction detection unit 3 detects spontaneous ventricle contraction, Increment is performed each time, and the ventricle contraction is continuously detected by the number of times (specifically, about 3 to 10 times) stored in the set value storage unit 64 of the number of times of continuous detection of ventricular contraction. Then, an output is issued from the ventricle contraction detection continuation number comparison unit 66.
- the output of the ventricular contraction detection continuation number comparison unit 66 is supplied to the AVD selection unit 63.
- the AVD selecting section 63 changes the setting value from the setting value of the first AVD storing section 61 to the setting of the second AVD storing section 62. Cut to value Change.
- the set value stored in the second AVD storage unit 62 is set to a set value smaller than the normal AVD (atrioventricular delay time) of about 150 ms, for example, 100 ms.
- the ventricle contraction detection unit 3 does not detect the contraction of the ventricle while the AVD timer 13 counts 100 ms.
- an output is obtained from the A / D comparison unit 15 each time.
- the output of the AVD comparison unit 15 is applied to the ventricle stimulating unit 2, the ventricular contraction detection continuation counter 65 and the QT time counting unit 71 (FIG. 12). Then, the QT time is measured as biological information representing the degree of excitement of the sympathetic nerve.
- the switching of the AVD selection unit 63 from the first AVD storage unit 61 to the AVD time setting value of the second AVD storage unit 62 is performed in order to measure the QT time. It is necessary to perform ventricular stimulation.
- the T-wave detector 72 of the QT time sensor 70 shown in Fig. 12 forcibly sends a trigger signal to the ventricular stimulator 2 and generates a T-wave only when the right ventricle 28 is stimulated.
- the output is sent to the QT timer section 71 and the counting of the QT timer section 71 is stopped.
- the measured QT time is sent from the QT time measuring section 71 to the heart rate threshold control section 19 in FIG. 11 and adjusted to a heart rate threshold value according to the patient's QT time.
- Fig. 15 shows an example of the heart rate threshold according to the QT time.
- the heart rate threshold is set to 100 beats / minute, and as the QT time becomes shorter, the heart rate threshold is decreased. In other words, the shorter the QT time, the higher the excitement of the sympathetic nerve, so the heart rate threshold for stimulating the vagus nerve is lowered.
- the operation of the seventh embodiment of the present invention will be described in detail with reference to the flowchart of FIG. First, the atrial stimulation interpulse timer 9 is started (step S50), and an initial value of the heart rate threshold of the heart rate threshold controller 19 is set (step S51). Then, the ventricular contraction detection continuation counter 65 is reset (step S52) to complete the initialization of the entire system.
- step S53 it is determined whether or not atrial contraction is detected by the atrial contraction detection unit 5 (step S53).
- the signal from the atrial contraction detecting section 5 is supplied to the heart rate measuring section 21 and the heart rate is measured (step S54).
- the output of the atrial contraction detecting unit 5 is also supplied to the atrial stimulation inter-pulse timer 9 via the OR circuit 12, and resets the atrial stimulation inter-pulse timer 9 (step S55).
- step S56 it is determined whether the heart rate measurement value has exceeded the heart rate threshold set in step 51 (step S56).
- the heart rate measured by the heart rate measurement unit 21 exceeds the heart rate threshold value (initial value) set in the heart rate threshold control unit 19
- an output is issued from the heart rate comparison unit 22 and the neural stimulation signal control is performed.
- Stimulation of the vagus nerve 32 is performed via the section 20 and the nerve stimulating section 6 (step S57).
- step S53 it is determined whether the atrial stimulation interval timer 9 has timed out, that is, the time measured by the atrial stimulation interval timer 9 is equal to the atrial stimulation interval. It is determined whether the set value stored in the interval set value storage unit 10 has been exceeded (step S58). Then, when it is determined that a time-out has occurred, an output is issued from the comparing section 11 to the atrial stimulating section 4 to perform atrial stimulation (step S59), and the heart rate measuring section 21 is reset. At the same time, the atrial stimulation interval timer 9 is reset (via the OR circuit 12) (step S60).
- step S56 If the measured heart rate does not reach the threshold for stimulating the vagus nerve 32 in the judgment step S56, the process proceeds to the next step S61 without stimulating the vagus nerve 32, and the judgment step S5 If it is determined in step 8 that the atrial stimulation interval timer 9 has not timed out, the flow returns to the decision step S53 to wait for the detection of atrial contraction. Then, when atrial stimulation is performed by the output of the comparing unit 11 and when atrial contraction is detected by the atrial contraction detecting unit 5, the AVD timer 13 starts counting (step S6). 1).
- step S62 If the ventricle contraction detection continuation counter 65 has reached the set value stored in the ventricle contraction detection continuation count set value storage unit 64, that is, stored in the ventricle contraction detection continuation count set value storage unit 64. It is determined whether or not the ventricle contraction is continuously detected as many as 3 to 10 times (step S62). When the count value of the ventricle contraction detection continuation counter 65 reaches the above set value, the output is given from the ventricle contraction detection continuation frequency comparison section 66 to the AVD selection section 63 and the AVD selection section. 63 selects the set value stored in the second AVD storage section 62 (step S63).
- the AVD timer 1 is set before the ventricle contraction detecting unit 3 detects spontaneous ventricular contraction. Since 3 reaches the set value of the second AVD storage unit 62, an output is obtained from the AVD comparison unit 15 and forced ventricular stimulation is performed, and the ventricle contraction detection continuation counter 65 is set. It is reset (step S64). If it is determined that the count value of the ventricle contraction detection continuation counter 65 does not reach the set value stored in the ventricle contraction detection continuation count set value storage unit 64 in the determination step S62, the first AVD is stored. The set value stored in section 61 is retained (step S65), and the process proceeds to the next step.
- step S66 it is determined whether or not the ventricle contraction is detected by the ventricle contraction detecting section 3 (step S66). If a ventricular contraction is detected in this determination step S66, the count of the AVD timer 13 is stopped (step S67), and the ventricle contraction detection continuation counter 65 is incremented. (Step S68). If it is determined in step S66 that no ventricular contraction has been detected, it is determined whether the AVD timer 13 has timed out, that is, the count value of the AVD timer 13 is determined by the AVD selection unit 6 3 It is determined whether or not exceeds the set value of the selected first AVD storage unit 61 or second AVD storage unit 62 (step S69).
- step S69 If it is determined in determination step S69 that the AVD timer 13 has not timed out, the detection of ventricular contraction is waited for. However, if the AVD timer 13 has timed out, the AVD comparison unit 15 , The ventricle is stimulated by the ventricle stimulating unit 2 (step S70), and the ventricle contraction detection continuation counter 65 is reset (step S71). The counting of the QT time counting section 71 is started (step S72).
- the T wave detector 72 of the QT time sensor 70 performs time differentiation of the intraventricular electrocardiogram within a predetermined period corresponding to the T wave portion, and has a negative slope from the differentiated waveform. Detects the time point at which the maximum is reached (step S73), and stops the timing of the QT timer section 71 (step S74).
- the measured value is sent to the heart rate threshold control unit 19 of the control unit 7 in Fig. 11 and the vagus nerve 32
- the upper limit of the heart rate threshold for stimulation is adjusted (step S75).
- Steps S50 to S71 in FIG. 16 and step S75 are the same as those in FIG. 16 and are denoted by the same reference numerals, and description thereof is omitted.
- step S69 when the AVD timer 13 times out and the output is output from the AVD comparison unit 15, the ventricle stimulation from the ventricle stimulation unit 2 is performed (step S7). 0), and the ventricle. Contraction detection continuation counter 65 is reset (step S71).
- an electrocardiogram area sensor 75 is used as a means for detecting biological information, and the integration circuit 7 of the electrocardiogram area sensor 75 after the above-mentioned ventricular stimulation is performed.
- the integration calculation of the ventricular electrocardiogram information is performed (step S76).
- the intraventricular electrocardiogram touches minus from the base potential, so that the result of the integration operation is detected as a negative signal output.
- it is determined whether or not a negative maximum value has been detected (step S77). If it is determined that a negative maximum value has been detected, then according to this negative maximum value, the position shown in FIG. The output is sent to the heart rate threshold control unit 19 to adjust the heart rate threshold when stimulating the vagus nerve 32 (step S75).
- FIG. 18 is a block diagram showing a ninth embodiment of the heart treatment apparatus of the present invention.
- the difference from the block diagram of the seventh and eighth embodiments of the present invention shown in FIGS. 11 to 13 is that the output of the ventricular contractile electrocardiogram sensor 60 is different from the heart rate threshold controller 1. The point is that it is supplied to not only 9 but also the nerve stimulation parameter table storage unit 80.
- the same parts as those in the block diagram of FIG. 11 are denoted by the same reference numerals.
- the ventricular systolic electrocardiogram sensor 60 includes the QT time sensor 70 shown in FIGS. 12 and 13. And an electrocardiogram area sensor 75 are used.
- an example using the QT time sensor 70 will be described.
- the electrocardiogram area sensor 75 may be used as in the case of FIG.
- the output of the ventricular systolic electrocardiogram sensor 60 is supplied to a heart rate threshold control unit 19 and a nerve stimulation parameter table storage unit 80.
- the QT time sensor 70 is used as the ventricular contractile electrocardiogram sensor
- the QT time measured at the time of ventricular contraction is sent to the heart rate threshold control unit 19 and the nerve stimulation parameter table storage unit 80.
- parameters for performing nerve stimulation according to the QT time such as the inter-pulse period, the pulse width, It determines the number of pulses, pulse voltage, pulse current, delay time, pause time, number of repetitions, and an appropriate combination of these.
- a stimulation parameter value or combination that enhances the excitation of the vagus nerve is selected with the expectation of a stronger protective effect. Configuration.
- the nerve stimulation parameter is controlled according to the biological information such as the QT time, and the threshold of the heart rate at which the vagus nerve is stimulated can be adjusted according to the biological information. Neural stimulation can be performed more finely according to the condition.
- FIG. 19 is a flowchart for explaining the ninth embodiment shown in FIG. It is almost the same as the flow diagram in Fig. 16 except that the steps for setting the neural stimulation parameters are between step S74 (QT time timer stop) and step S75 (heart rate threshold adjustment). S78 is added.
- the ninth embodiment of the present invention adjusts the heart rate threshold (upper limit) when stimulating the vagus nerve according to the patient's biological information. . _
- the control of the nerve stimulation parameter is not limited to the control using the ventricular contractile electrocardiogram sensor.
- each sensor output is stored in the nerve stimulation parameter table storage unit. It can be realized by supplying.
- the present invention is not limited to these embodiments.
- the heart rate measuring means measures the heart rate.
- this may be replaced with a heart rate interval. That is, the heart rate is the number of heartbeats per minute, which can be calculated from the interval between two consecutive heartbeats. Specifically, assuming that the heart rate (time Z) is A and the heartbeat interval (seconds) is B, the two have the following relationship.
- the heart rate threshold in the embodiment is treated as an upper limit for a heart rate and as a lower limit for a heart rate interval.
- the degree of sympathetic nerve excitement of a patient due to exercise or stress is known from various biological information, Since the vagus nerve can be appropriately and finely stimulated according to the degree of excitement, enormous effects such as avoiding side effects due to nerve stimulation and excessive reduction in heart rate and saving power consumption can be obtained.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/233,109 US7336997B2 (en) | 2003-03-24 | 2005-09-23 | Heart treatment equipment and heart treatment method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-81017 | 2003-03-24 | ||
JP2003081017A JP4252830B2 (ja) | 2003-03-24 | 2003-03-24 | 心臓治療装置 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/233,109 Continuation US7336997B2 (en) | 2003-03-24 | 2005-09-23 | Heart treatment equipment and heart treatment method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004084993A1 true WO2004084993A1 (ja) | 2004-10-07 |
Family
ID=33094885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/003766 WO2004084993A1 (ja) | 2003-03-24 | 2004-03-19 | 心臓治療装置及び心臓治療方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7336997B2 (ja) |
JP (1) | JP4252830B2 (ja) |
WO (1) | WO2004084993A1 (ja) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006121929A1 (en) * | 2005-05-10 | 2006-11-16 | Cardiac Pacemakers, Inc. | Therapy delivery system |
US7647114B2 (en) | 2003-12-24 | 2010-01-12 | Cardiac Pacemakers, Inc. | Baroreflex modulation based on monitored cardiovascular parameter |
US7706884B2 (en) | 2003-12-24 | 2010-04-27 | Cardiac Pacemakers, Inc. | Baroreflex stimulation synchronized to circadian rhythm |
US7747323B2 (en) | 2004-06-08 | 2010-06-29 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
US7783353B2 (en) | 2003-12-24 | 2010-08-24 | Cardiac Pacemakers, Inc. | Automatic neural stimulation modulation based on activity and circadian rhythm |
US7787946B2 (en) | 2003-08-18 | 2010-08-31 | Cardiac Pacemakers, Inc. | Patient monitoring, diagnosis, and/or therapy systems and methods |
US7869881B2 (en) | 2003-12-24 | 2011-01-11 | Cardiac Pacemakers, Inc. | Baroreflex stimulator with integrated pressure sensor |
US8000793B2 (en) | 2003-12-24 | 2011-08-16 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation based on cardiac activity |
US8002553B2 (en) | 2003-08-18 | 2011-08-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
US8024050B2 (en) | 2003-12-24 | 2011-09-20 | Cardiac Pacemakers, Inc. | Lead for stimulating the baroreceptors in the pulmonary artery |
US8121693B2 (en) | 2003-12-24 | 2012-02-21 | Cardiac Pacemakers, Inc. | Baroreflex stimulation to treat acute myocardial infarction |
US8126560B2 (en) | 2003-12-24 | 2012-02-28 | Cardiac Pacemakers, Inc. | Stimulation lead for stimulating the baroreceptors in the pulmonary artery |
US8131362B2 (en) | 2005-03-11 | 2012-03-06 | Cardiac Pacemakers, Inc. | Combined neural stimulation and cardiac resynchronization therapy |
US8170668B2 (en) | 2006-07-14 | 2012-05-01 | Cardiac Pacemakers, Inc. | Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy |
US8190257B2 (en) | 2005-04-05 | 2012-05-29 | Cardiac Pacemakers, Inc. | System to treat AV-conducted ventricular tachyarrhythmia |
US8200331B2 (en) | 2004-11-04 | 2012-06-12 | Cardiac Pacemakers, Inc. | System and method for filtering neural stimulation |
US8548585B2 (en) | 2009-12-08 | 2013-10-01 | Cardiac Pacemakers, Inc. | Concurrent therapy detection in implantable medical devices |
US8606356B2 (en) | 2003-09-18 | 2013-12-10 | Cardiac Pacemakers, Inc. | Autonomic arousal detection system and method |
US8660648B2 (en) | 2005-10-24 | 2014-02-25 | Cardiac Pacemakers, Inc. | Implantable and rechargeable neural stimulator |
US9020595B2 (en) | 2003-12-24 | 2015-04-28 | Cardiac Pacemakers, Inc. | Baroreflex activation therapy with conditional shut off |
US9211412B2 (en) | 2005-04-05 | 2015-12-15 | Cardiac Pacemakers, Inc. | Closed loop neural stimulation synchronized to cardiac cycles |
US11369794B2 (en) | 2005-05-25 | 2022-06-28 | Cardiac Pacemakers, Inc. | Implantable neural stimulator with mode switching |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US6907295B2 (en) | 2001-08-31 | 2005-06-14 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US6684105B2 (en) * | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US20090005845A1 (en) * | 2007-06-26 | 2009-01-01 | Tamir Ben David | Intra-Atrial parasympathetic stimulation |
US8615294B2 (en) * | 2008-08-13 | 2013-12-24 | Bio Control Medical (B.C.M.) Ltd. | Electrode devices for nerve stimulation and cardiac sensing |
US7734355B2 (en) * | 2001-08-31 | 2010-06-08 | Bio Control Medical (B.C.M.) Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US7778703B2 (en) * | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Selective nerve fiber stimulation for treating heart conditions |
US8571653B2 (en) * | 2001-08-31 | 2013-10-29 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
US7885709B2 (en) * | 2001-08-31 | 2011-02-08 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation for treating disorders |
US7904176B2 (en) * | 2006-09-07 | 2011-03-08 | Bio Control Medical (B.C.M.) Ltd. | Techniques for reducing pain associated with nerve stimulation |
US8565896B2 (en) | 2010-11-22 | 2013-10-22 | Bio Control Medical (B.C.M.) Ltd. | Electrode cuff with recesses |
US7974693B2 (en) | 2001-08-31 | 2011-07-05 | Bio Control Medical (B.C.M.) Ltd. | Techniques for applying, configuring, and coordinating nerve fiber stimulation |
US7778711B2 (en) * | 2001-08-31 | 2010-08-17 | Bio Control Medical (B.C.M.) Ltd. | Reduction of heart rate variability by parasympathetic stimulation |
US20050065553A1 (en) * | 2003-06-13 | 2005-03-24 | Omry Ben Ezra | Applications of vagal stimulation |
US7844346B2 (en) * | 2002-05-23 | 2010-11-30 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US7561922B2 (en) * | 2004-12-22 | 2009-07-14 | Biocontrol Medical Ltd. | Construction of electrode assembly for nerve control |
US7321793B2 (en) * | 2003-06-13 | 2008-01-22 | Biocontrol Medical Ltd. | Vagal stimulation for atrial fibrillation therapy |
US7885711B2 (en) * | 2003-06-13 | 2011-02-08 | Bio Control Medical (B.C.M.) Ltd. | Vagal stimulation for anti-embolic therapy |
US7627384B2 (en) * | 2004-11-15 | 2009-12-01 | Bio Control Medical (B.C.M.) Ltd. | Techniques for nerve stimulation |
US8880192B2 (en) | 2012-04-02 | 2014-11-04 | Bio Control Medical (B.C.M.) Ltd. | Electrode cuffs |
US8718791B2 (en) | 2003-05-23 | 2014-05-06 | Bio Control Medical (B.C.M.) Ltd. | Electrode cuffs |
US8060197B2 (en) * | 2003-05-23 | 2011-11-15 | Bio Control Medical (B.C.M.) Ltd. | Parasympathetic stimulation for termination of non-sinus atrial tachycardia |
US8116883B2 (en) * | 2003-06-04 | 2012-02-14 | Synecor Llc | Intravascular device for neuromodulation |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP2007530586A (ja) * | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
CA2998199A1 (en) * | 2004-06-01 | 2005-12-15 | Kwalata Trading Limited | Methods for use with stem cells involving culturing on a surface with antibodies |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
EP2298410B1 (en) | 2004-12-27 | 2013-10-09 | The Feinstein Institute for Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
US8609082B2 (en) | 2005-01-25 | 2013-12-17 | Bio Control Medical Ltd. | Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesis |
US7840266B2 (en) | 2005-03-11 | 2010-11-23 | Cardiac Pacemakers, Inc. | Integrated lead for applying cardiac resynchronization therapy and neural stimulation therapy |
EP1863564B1 (en) * | 2005-03-11 | 2016-11-23 | Cardiac Pacemakers, Inc. | Combined neural stimulation and cardiac resynchronization therapy |
US7660628B2 (en) | 2005-03-23 | 2010-02-09 | Cardiac Pacemakers, Inc. | System to provide myocardial and neural stimulation |
JP4812319B2 (ja) * | 2005-03-31 | 2011-11-09 | テルモ株式会社 | 神経刺激強度設定装置および心臓治療装置 |
US7881782B2 (en) * | 2005-04-20 | 2011-02-01 | Cardiac Pacemakers, Inc. | Neural stimulation system to prevent simultaneous energy discharges |
US7640057B2 (en) * | 2005-04-25 | 2009-12-29 | Cardiac Pacemakers, Inc. | Methods of providing neural markers for sensed autonomic nervous system activity |
US8032206B1 (en) * | 2005-10-20 | 2011-10-04 | Pacesetter, Inc. | Use of motion sensor for dynamic updating of heart detection threshold |
US9566447B2 (en) * | 2005-12-28 | 2017-02-14 | Cardiac Pacemakers, Inc. | Neural stimulation system for reducing atrial proarrhythmia |
TW200734462A (en) | 2006-03-08 | 2007-09-16 | In Motion Invest Ltd | Regulating stem cells |
US7956421B2 (en) * | 2008-03-13 | 2011-06-07 | Tela Innovations, Inc. | Cross-coupled transistor layouts in restricted gate level layout architecture |
US7689286B2 (en) * | 2006-05-02 | 2010-03-30 | Cardiac Pacemakers, Inc. | Myocardium conditioning using myocardial and parasympathetic stimulation |
US8103341B2 (en) * | 2006-08-25 | 2012-01-24 | Cardiac Pacemakers, Inc. | System for abating neural stimulation side effects |
EP2129352B1 (en) * | 2007-03-13 | 2016-03-09 | The Feinstein Institute for Medical Research | Treatment of inflammation by non-invasive stimulation |
US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
US7925352B2 (en) | 2008-03-27 | 2011-04-12 | Synecor Llc | System and method for transvascularly stimulating contents of the carotid sheath |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US20090275997A1 (en) * | 2008-05-01 | 2009-11-05 | Michael Allen Faltys | Vagus nerve stimulation electrodes and methods of use |
EP2355893B1 (en) | 2008-11-18 | 2013-12-25 | Setpoint Medical Corporation | Devices for optimizing electrode placement for anti-inflamatory stimulation |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
AU2010336337B2 (en) | 2009-12-23 | 2016-02-04 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
EP2701795B1 (en) | 2011-04-28 | 2020-12-09 | Interventional Autonomics Corporation | Neuromodulation systems for treating acute heart failure syndromes |
WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US9026214B2 (en) | 2011-06-23 | 2015-05-05 | Cardiac Pacemakers, Inc. | Systems and methods for avoiding aspiration during autonomic modulation therapy |
US20130072995A1 (en) | 2011-07-11 | 2013-03-21 | Terrance Ransbury | Catheter system for acute neuromodulation |
US9446240B2 (en) | 2011-07-11 | 2016-09-20 | Interventional Autonomics Corporation | System and method for neuromodulation |
WO2013028274A2 (en) | 2011-07-11 | 2013-02-28 | Synecor Llc | System and method for neuromodulation |
JP6000535B2 (ja) * | 2011-12-06 | 2016-09-28 | オリンパス株式会社 | 刺激制御装置、刺激発生装置、ならびに神経刺激システム |
US8577458B1 (en) | 2011-12-07 | 2013-11-05 | Cyberonics, Inc. | Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with leadless heart rate monitoring |
US8918190B2 (en) | 2011-12-07 | 2014-12-23 | Cyberonics, Inc. | Implantable device for evaluating autonomic cardiovascular drive in a patient suffering from chronic cardiac dysfunction |
US10188856B1 (en) | 2011-12-07 | 2019-01-29 | Cyberonics, Inc. | Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction |
US8918191B2 (en) | 2011-12-07 | 2014-12-23 | Cyberonics, Inc. | Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration |
US8700150B2 (en) | 2012-01-17 | 2014-04-15 | Cyberonics, Inc. | Implantable neurostimulator for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
US8688212B2 (en) | 2012-07-20 | 2014-04-01 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing bradycardia through vagus nerve stimulation |
US9452290B2 (en) | 2012-11-09 | 2016-09-27 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing tachyarrhythmia through vagus nerve stimulation |
US8923964B2 (en) | 2012-11-09 | 2014-12-30 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for enhancing heart failure patient awakening through vagus nerve stimulation |
US9643008B2 (en) * | 2012-11-09 | 2017-05-09 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for enhancing post-exercise recovery through vagus nerve stimulation |
US9643011B2 (en) | 2013-03-14 | 2017-05-09 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing tachyarrhythmic risk during sleep through vagus nerve stimulation |
US9370660B2 (en) | 2013-03-29 | 2016-06-21 | Rainbow Medical Ltd. | Independently-controlled bidirectional nerve stimulation |
US9999773B2 (en) | 2013-10-30 | 2018-06-19 | Cyberonics, Inc. | Implantable neurostimulator-implemented method utilizing multi-modal stimulation parameters |
US9511228B2 (en) | 2014-01-14 | 2016-12-06 | Cyberonics, Inc. | Implantable neurostimulator-implemented method for managing hypertension through renal denervation and vagus nerve stimulation |
US9950169B2 (en) | 2014-04-25 | 2018-04-24 | Cyberonics, Inc. | Dynamic stimulation adjustment for identification of a neural fulcrum |
US9713719B2 (en) | 2014-04-17 | 2017-07-25 | Cyberonics, Inc. | Fine resolution identification of a neural fulcrum for the treatment of chronic cardiac dysfunction |
US9415224B2 (en) | 2014-04-25 | 2016-08-16 | Cyberonics, Inc. | Neurostimulation and recording of physiological response for the treatment of chronic cardiac dysfunction |
US9272143B2 (en) | 2014-05-07 | 2016-03-01 | Cyberonics, Inc. | Responsive neurostimulation for the treatment of chronic cardiac dysfunction |
US9409024B2 (en) | 2014-03-25 | 2016-08-09 | Cyberonics, Inc. | Neurostimulation in a neural fulcrum zone for the treatment of chronic cardiac dysfunction |
US9737716B2 (en) | 2014-08-12 | 2017-08-22 | Cyberonics, Inc. | Vagus nerve and carotid baroreceptor stimulation system |
US9533153B2 (en) | 2014-08-12 | 2017-01-03 | Cyberonics, Inc. | Neurostimulation titration process |
US9770599B2 (en) | 2014-08-12 | 2017-09-26 | Cyberonics, Inc. | Vagus nerve stimulation and subcutaneous defibrillation system |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US9504832B2 (en) | 2014-11-12 | 2016-11-29 | Cyberonics, Inc. | Neurostimulation titration process via adaptive parametric modification |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US20160310740A1 (en) * | 2015-04-24 | 2016-10-27 | Guy P. Curtis | Method for stimulating heart muscle activity during the refractory period |
US20180184963A1 (en) * | 2015-05-19 | 2018-07-05 | Beyond Verbal Communication Ltd | System and method for improving emotional well-being by vagal nerve stimulation |
EP3368148B1 (en) * | 2015-10-26 | 2022-09-14 | Cardiac Pacemakers, Inc. | Multi-sensor based cardiac stimulation |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
FR3047669B1 (fr) * | 2016-02-12 | 2021-10-01 | Chu De Rennes Centre Hospitalier Univ De Rennes | Systeme et procede d'application de signaux a des sondes de nerfs vagues pour la prevention de certaines consequences de l'epilepsie |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
US11235157B2 (en) * | 2018-12-14 | 2022-02-01 | Cardiac Pacemakers, Inc. | Heart rate indicated atrioventricular delay optimization |
US11338143B2 (en) * | 2019-03-20 | 2022-05-24 | Neuroceuticals, Inc. | Control apparatus for treating myocardial infarction and control method for treating myocardial infarction |
JP2023500778A (ja) * | 2019-09-26 | 2023-01-11 | ヴィスカルディア インコーポレイテッド | 横隔膜刺激によって心機能に影響を及ぼすためのおよび横隔膜の健康をモニタリングするための埋め込み型医療システム、機器、および方法 |
US11167145B2 (en) | 2019-10-30 | 2021-11-09 | Guy P. Curtis And Frances L. Curtis Trust | System and method for indirect measurement of ventricular contractility |
US11923078B2 (en) | 2019-11-01 | 2024-03-05 | Terumo Cardiovascular Systems Corporation | Semi-autonomous medical systems and methods |
EP4126191A1 (en) | 2020-03-27 | 2023-02-08 | VisCardia, Inc. | Implantable medical systems, devices and methods for delivering asymptomatic diaphragmatic stimulation |
US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62137068A (ja) * | 1985-08-28 | 1987-06-19 | ラウル・チリフエ | 生理的条件に適応した心臓ペ−スメ−カ− |
JPH0838626A (ja) * | 1994-06-24 | 1996-02-13 | Pacesetter Ab | 上室心臓治療装置 |
JPH0852121A (ja) * | 1994-06-24 | 1996-02-27 | Pacesetter Ab | 不整脈検知装置 |
JPH11319119A (ja) * | 1998-05-11 | 1999-11-24 | Cardio Pacing Research Laboratory:Kk | 心臓ペースメーカー |
US6473644B1 (en) * | 1999-10-13 | 2002-10-29 | Cyberonics, Inc. | Method to enhance cardiac capillary growth in heart failure patients |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6266555B1 (en) * | 1998-05-07 | 2001-07-24 | Medtronic, Inc. | Single complex electrogram display having a sensing threshold for an implantable medical device |
US6873870B2 (en) * | 2001-04-30 | 2005-03-29 | Medtronic, Inc. | Methods for adjusting cardiac detection criteria and implantable medical devices using same |
US6622041B2 (en) * | 2001-08-21 | 2003-09-16 | Cyberonics, Inc. | Treatment of congestive heart failure and autonomic cardiovascular drive disorders |
-
2003
- 2003-03-24 JP JP2003081017A patent/JP4252830B2/ja not_active Expired - Fee Related
-
2004
- 2004-03-19 WO PCT/JP2004/003766 patent/WO2004084993A1/ja active Application Filing
-
2005
- 2005-09-23 US US11/233,109 patent/US7336997B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62137068A (ja) * | 1985-08-28 | 1987-06-19 | ラウル・チリフエ | 生理的条件に適応した心臓ペ−スメ−カ− |
JPH0838626A (ja) * | 1994-06-24 | 1996-02-13 | Pacesetter Ab | 上室心臓治療装置 |
JPH0852121A (ja) * | 1994-06-24 | 1996-02-27 | Pacesetter Ab | 不整脈検知装置 |
JPH11319119A (ja) * | 1998-05-11 | 1999-11-24 | Cardio Pacing Research Laboratory:Kk | 心臓ペースメーカー |
US6473644B1 (en) * | 1999-10-13 | 2002-10-29 | Cyberonics, Inc. | Method to enhance cardiac capillary growth in heart failure patients |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7787946B2 (en) | 2003-08-18 | 2010-08-31 | Cardiac Pacemakers, Inc. | Patient monitoring, diagnosis, and/or therapy systems and methods |
US8915741B2 (en) | 2003-08-18 | 2014-12-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
US8002553B2 (en) | 2003-08-18 | 2011-08-23 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
US9014819B2 (en) | 2003-09-18 | 2015-04-21 | Cardiac Pacemakers, Inc. | Autonomic arousal detection system and method |
US8606356B2 (en) | 2003-09-18 | 2013-12-10 | Cardiac Pacemakers, Inc. | Autonomic arousal detection system and method |
US8874211B2 (en) | 2003-12-23 | 2014-10-28 | Cardiac Pacemakers, Inc. | Hypertension therapy based on activity and circadian rhythm |
US8126560B2 (en) | 2003-12-24 | 2012-02-28 | Cardiac Pacemakers, Inc. | Stimulation lead for stimulating the baroreceptors in the pulmonary artery |
US9265948B2 (en) | 2003-12-24 | 2016-02-23 | Cardiac Pacemakers, Inc. | Automatic neural stimulation modulation based on activity |
US8818513B2 (en) | 2003-12-24 | 2014-08-26 | Cardiac Pacemakers, Inc. | Baroreflex stimulation synchronized to circadian rhythm |
US7869881B2 (en) | 2003-12-24 | 2011-01-11 | Cardiac Pacemakers, Inc. | Baroreflex stimulator with integrated pressure sensor |
US8000793B2 (en) | 2003-12-24 | 2011-08-16 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation based on cardiac activity |
US11154716B2 (en) | 2003-12-24 | 2021-10-26 | Cardiac Pacemakers, Inc. | System for providing stimulation pattern to modulate neural activity |
US10369367B2 (en) | 2003-12-24 | 2019-08-06 | Cardiac Pacemakers, Inc. | System for providing stimulation pattern to modulate neural activity |
US8121693B2 (en) | 2003-12-24 | 2012-02-21 | Cardiac Pacemakers, Inc. | Baroreflex stimulation to treat acute myocardial infarction |
US9950170B2 (en) | 2003-12-24 | 2018-04-24 | Cardiac Pacemakers, Inc. | System for providing stimulation pattern to modulate neural activity |
US8805501B2 (en) | 2003-12-24 | 2014-08-12 | Cardiac Pacemakers, Inc. | Baroreflex stimulation to treat acute myocardial infarction |
US7706884B2 (en) | 2003-12-24 | 2010-04-27 | Cardiac Pacemakers, Inc. | Baroreflex stimulation synchronized to circadian rhythm |
US8131373B2 (en) | 2003-12-24 | 2012-03-06 | Cardiac Pacemakers, Inc. | Baroreflex stimulation synchronized to circadian rhythm |
US9561373B2 (en) | 2003-12-24 | 2017-02-07 | Cardiac Pacemakers, Inc. | System to stimulate a neural target and a heart |
US7783353B2 (en) | 2003-12-24 | 2010-08-24 | Cardiac Pacemakers, Inc. | Automatic neural stimulation modulation based on activity and circadian rhythm |
US7647114B2 (en) | 2003-12-24 | 2010-01-12 | Cardiac Pacemakers, Inc. | Baroreflex modulation based on monitored cardiovascular parameter |
US8024050B2 (en) | 2003-12-24 | 2011-09-20 | Cardiac Pacemakers, Inc. | Lead for stimulating the baroreceptors in the pulmonary artery |
US8285389B2 (en) | 2003-12-24 | 2012-10-09 | Cardiac Pacemakers, Inc. | Automatic neural stimulation modulation based on motion and physiological activity |
US8442640B2 (en) | 2003-12-24 | 2013-05-14 | Cardiac Pacemakers, Inc. | Neural stimulation modulation based on monitored cardiovascular parameter |
US8626301B2 (en) | 2003-12-24 | 2014-01-07 | Cardiac Pacemakers, Inc. | Automatic baroreflex modulation based on cardiac activity |
US8457746B2 (en) | 2003-12-24 | 2013-06-04 | Cardiac Pacemakers, Inc. | Implantable systems and devices for providing cardiac defibrillation and apnea therapy |
US8473076B2 (en) | 2003-12-24 | 2013-06-25 | Cardiac Pacemakers, Inc. | Lead for stimulating the baroreceptors in the pulmonary artery |
US9440078B2 (en) | 2003-12-24 | 2016-09-13 | Cardiac Pacemakers, Inc. | Neural stimulation modulation based on monitored cardiovascular parameter |
US8805513B2 (en) | 2003-12-24 | 2014-08-12 | Cardiac Pacemakers, Inc. | Neural stimulation modulation based on monitored cardiovascular parameter |
US9020595B2 (en) | 2003-12-24 | 2015-04-28 | Cardiac Pacemakers, Inc. | Baroreflex activation therapy with conditional shut off |
US8442638B2 (en) | 2004-06-08 | 2013-05-14 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
US9872987B2 (en) | 2004-06-08 | 2018-01-23 | Cardiac Pacemakers, Inc. | Method and system for treating congestive heart failure |
US7747323B2 (en) | 2004-06-08 | 2010-06-29 | Cardiac Pacemakers, Inc. | Adaptive baroreflex stimulation therapy for disordered breathing |
US8200332B2 (en) | 2004-11-04 | 2012-06-12 | Cardiac Pacemakers, Inc. | System and method for filtering neural stimulation |
US8200331B2 (en) | 2004-11-04 | 2012-06-12 | Cardiac Pacemakers, Inc. | System and method for filtering neural stimulation |
US8768462B2 (en) | 2004-11-04 | 2014-07-01 | Cardiac Pacemakers, Inc. | System and method for filtering neural stimulation |
US8131362B2 (en) | 2005-03-11 | 2012-03-06 | Cardiac Pacemakers, Inc. | Combined neural stimulation and cardiac resynchronization therapy |
US8190257B2 (en) | 2005-04-05 | 2012-05-29 | Cardiac Pacemakers, Inc. | System to treat AV-conducted ventricular tachyarrhythmia |
US9211412B2 (en) | 2005-04-05 | 2015-12-15 | Cardiac Pacemakers, Inc. | Closed loop neural stimulation synchronized to cardiac cycles |
US9962548B2 (en) | 2005-04-05 | 2018-05-08 | Cardiac Pacemakers, Inc. | Closed loop neural stimulation synchronized to cardiac cycles |
US8909337B2 (en) | 2005-04-05 | 2014-12-09 | Cardiac Pacemakers, Inc. | System to treat AV-conducted ventricular tachyarrhythmia |
US8131359B2 (en) | 2005-05-10 | 2012-03-06 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
WO2006121929A1 (en) * | 2005-05-10 | 2006-11-16 | Cardiac Pacemakers, Inc. | Therapy delivery system |
EP2179765A2 (en) * | 2005-05-10 | 2010-04-28 | Cardiac Pacemakers, Inc. | Therapy delivery system |
EP2179764A3 (en) * | 2005-05-10 | 2014-03-26 | Cardiac Pacemakers, Inc. | Therapy delivery system |
EP2179764A2 (en) * | 2005-05-10 | 2010-04-28 | Cardiac Pacemakers, Inc. | Therapy delivery system |
EP2179765A3 (en) * | 2005-05-10 | 2014-04-16 | Cardiac Pacemakers, Inc. | Therapy delivery system |
US8504149B2 (en) | 2005-05-10 | 2013-08-06 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
US9504836B2 (en) | 2005-05-10 | 2016-11-29 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
US7493161B2 (en) | 2005-05-10 | 2009-02-17 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
US8805494B2 (en) | 2005-05-10 | 2014-08-12 | Cardiac Pacemakers, Inc. | System and method to deliver therapy in presence of another therapy |
US11369794B2 (en) | 2005-05-25 | 2022-06-28 | Cardiac Pacemakers, Inc. | Implantable neural stimulator with mode switching |
US11890476B2 (en) | 2005-05-25 | 2024-02-06 | Cardiac Pacemakers, Inc. | Implantable neural stimulator with mode switching |
US8660648B2 (en) | 2005-10-24 | 2014-02-25 | Cardiac Pacemakers, Inc. | Implantable and rechargeable neural stimulator |
US8170668B2 (en) | 2006-07-14 | 2012-05-01 | Cardiac Pacemakers, Inc. | Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy |
US8548585B2 (en) | 2009-12-08 | 2013-10-01 | Cardiac Pacemakers, Inc. | Concurrent therapy detection in implantable medical devices |
US9227068B2 (en) | 2009-12-08 | 2016-01-05 | Cardiac Pacemakers, Inc. | Concurrent therapy detection in implantable medical devices |
Also Published As
Publication number | Publication date |
---|---|
JP4252830B2 (ja) | 2009-04-08 |
US20060052831A1 (en) | 2006-03-09 |
US7336997B2 (en) | 2008-02-26 |
JP2004283463A (ja) | 2004-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4252830B2 (ja) | 心臓治療装置 | |
US7142917B2 (en) | Heart treatment equipment and method for preventing fatal arrhythmia | |
US7092755B2 (en) | System and method of cardiac pacing during sleep apnea | |
JP4926064B2 (ja) | モニタされた心臓血管パラメータに基づいた圧反射調節 | |
US7437192B2 (en) | System and method for detecting heart failure and pulmonary edema based on ventricular end-diastolic pressure using an implantable medical device | |
US7179229B1 (en) | System and method for apnea detection using blood pressure detected via an implantable medical system | |
EP1624929B1 (en) | Apparatus to monitor pulmonary edema | |
US6625492B2 (en) | Implantable cardiac stimulation device with detection and therapy for patients with vasovagal syncope | |
US20100114227A1 (en) | Systems and Methds for Use by an Implantable Medical Device for Controlling Vagus Nerve Stimulation Based on Heart Rate Reduction Curves and Thresholds to Mitigate Heart Failure | |
US6606517B1 (en) | Methods and apparatus for preventing atrial arrhythmias by overdrive pacing and prolonging atrial refractoriness using an implantable cardiac stimulation device | |
US6647295B2 (en) | Implantable cardiac stimulation device with detection and therapy for patients with vasovagal syncope | |
JP2005501617A (ja) | 電気刺激により心臓のメカニカル機能不全を治療するシステム | |
US6510342B1 (en) | Methods and apparatus for preventing atrial arrhythmias by overdrive pacing multiple heart tissue sites using an implantable cardiac stimulation device | |
US8401642B2 (en) | Pressure-driven intermittent pacing therapy | |
US8805497B2 (en) | Titrated intermittent pacing therapy | |
WO2010054359A2 (en) | Reverse hysteresis and mode switching for intermittent pacing therapy | |
JP2004173790A (ja) | 心臓治療装置 | |
WO2004084990A1 (ja) | 心臓治療装置及び心臓治療方法 | |
JP4252826B2 (ja) | 心臓治療装置 | |
US10589101B2 (en) | System and method for detecting tamponade | |
US6694188B1 (en) | Dynamic control of overdrive pacing based on degree of randomness within heart rate | |
JP6719024B2 (ja) | 活動レベルペーシングのための植込み型医療装置 | |
EP3265172A1 (en) | Systems and methods for treating cardiac arrhythmias | |
JP2020512915A (ja) | 感知された心拍数に基づくペーシングパルスエネルギー調整を用いた心臓ペースメーカ | |
JP4177086B2 (ja) | 心臓治療装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11233109 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11233109 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |